Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy

Cancer Letters

Volumn 251, Issue 2, 2007, Pages 330-338

  Nicolini, Andrea ^a   Carpi, Angelo ^a   Rossi, Giuseppe ^b  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Cellular immunity; Cytokines; Endocrine dependent metastatic breast cancer

Indexed keywords

BETA INTERFERON; C REACTIVE PROTEIN; CD16 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; FLUOROURACIL; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; LETROZOLE; METHOTREXATE; TAMOXIFEN; TOREMIFENE; TRANSFORMING GROWTH FACTOR BETA1;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; FEMALE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; NATURAL KILLER T CELL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; C-REACTIVE PROTEIN; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERFERON-BETA; INTERLEUKIN-2; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; SURVIVAL ANALYSIS; TAMOXIFEN; TOREMIFENE;

EID: 34247626802     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.12.002     Document Type: Article

References (21)

1. Chia S.K.L., Speers C., Kang A., D'Yachova Y., Malfair Taylor S., Barnett J., Coldman A., et al. The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort. Proc. ASCO (2003) 89
2. Nicolini A., and Carpi A. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial. Biomed. Pharmacother. 59 (2005) 253-263
3. Nicolini A., Carpi A., and Rossi G. An immunotherapy schedule in endocrine-dependent metastatic breast cancer: correlation between clinical course and immunological parameters. J. Immunother. 28 (2005) 276-279
4. Kiang D.T., Kollander R.E., Thomas T., and Kennedy B.J. Up-regulation of estrogen receptors by nonsteroidal antiestrogens in human breast cancer. Cancer Res. 49 (1989) 5312-5316
5. Noguchi S., Motomura K., Inaji H., Imaoka S., and Koyama H. Up-regulation of estrogen receptor by tamoxifen in human breast cancer. Cancer 71 (1993) 1266-1272
6. Lonning P.E., Bajetta E., Murray R., Tubiana-Hulin M., Eisenberg P.D., Mickiewicz E., Celio L., et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J. Clin. Oncol. 18 (2000) 2234-2244
7. Nicolini A., Carpi A., Ferrari P., and Pieri L. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations. Tumour Biol. 24 (2003) 275-280
8. Nicolini A., Carpi A., and Tarro G. Biomolecular markers of breast cancer. Front Biosci. 11 (2006) 1818-1843
9. Barak V., Kalickman I., Nisman B., Farbstein H., Fridlender Z.G., Baider L., Kaplan A., et al. Changes in cytokine production of breast cancer patients treated with interferons. Cytokine 10 (1998) 977-983
10. S-Plus 2000 Data Analysis Products Division, MathSoft Seattle, WA.
11. Yamamoto N., Watanabe T., Katsumata N., Omuro Y., Ando M., Fukuda H., Takue Y., et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J. Clin. Oncol. 16 (1998) 2401-2408
12. Fossati R., Confalonieri C., Torri V., Ghislandi E., Penna A., Pistotti V., Tinazzi A., et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J. Clin. Oncol. 16 (1998) 3439-3460
13. Bonneterre J., Thurlimann B., Robertson J.F., Krzakowski M., Mauriac L., Koralewski P., Vergote I., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J. Clin. Oncol. 18 (2000) 3748-3757
14. Israel L., Cour V., Pihan I., Morere J.F., Breau J.L., Franks C.R., Palmer P., et al. Some theoretical and practical limitations of interleukin-2. Ten cases of advanced breast cancer treated with continuous infusion of IL-2. Cancer Treat. Rev. 16A (1989) 169-171
15. Fleming G.F., Meropol N.J., Rosner G.L., Hollis D.R., Carson III W.E., Caligiuri M., Mortimer J., et al. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin. Cancer Res. 8 (2002) 3718-3727 (Erratum in: Clin. Cancer Res. 9 (2003) 1573)
16. In: Abbas A.K., Lichtman A.H., and Pober J.S. (Eds). Cellular and molecular immunology (Chapter 12). second ed. (1994), WB Saunders Company, Philadelphia, PA 315-346
17. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., Bhattacharya R., et al. Nat. Med. 10 (2004) 48-54
18. Sato T., McCue P., Masuoka K., Salwen S., Lattime E.C., Mastrangelo M.J., and Berd D. Interleukin 10 production by human melanoma. Clin. Cancer Res. 2 (1996) 1383-1390
19. Patel K.B., Berd D., Mastrangelo M.J., Terai M., and Sato T. Prognostic importance of interleukin-10 (IL-10) production by metastatic melanoma tissues from patients receiving autologous vaccine therapy. Proceedings ASCO (2002) 432a abs 1726
20. Koli K.M., and Arteaga C.L. Complex role of tumor cell transforming growth factor (TGF)-beta s on breast carcinoma progression. J. Mammary Gland Biol. Neoplasia 1 (1996) 373-380
21. Oh Y., Muller H.L., Ng L., and Rosenfeld R.G. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J. Biol. Chem. 9 (1995) 13589-13592